A market worth tens of billions is about to be entered by BMS.

 

On October 12, BMS revealed that RYZ101, its star asset in radiopharmaceuticals, met its primary endpoint in a prespecified interim analysis of a Phase III clinical trial. This is undoubtedly a highly landmark achievement for the giant.

 

It is evident to all that the patent cliffs for Opdivo and Eliquis — its two "cash cows" — are closing in, causing market skepticism about BMS's growth prospects to rise repeatedly. This can be seen in BMS's stock performance over the past few years, which is in turn related to its successive R&D setbacks.

 

RYZ101's path to success was not smooth either. From clinical trials being forced to pause due to isotope shortages, to interim analyses being repeatedly delayed, each setback has weighed on investor confidence.

 

Fortunately, at this moment, a positive Phase III result not only gives a $4.1 billion bet a glimmer of return, but also pushes BMS onto the core track of the global radiopharmaceutical race. With BMS's entry imminent, the radiopharmaceutical track long dominated by giants like Novartis may be in for a new reshuffling.

 

Chapter 1: A Long Climb

 

The story of RYZ101 begins with a therapeutic weapon.

 

GEP-NETs (gastroenteropancreatic neuroendocrine tumors) are a rare but challenging class of tumors, with a global prevalence of fewer than 200,000 people. These tumors typically grow slowly, but once they reach an advanced stage and begin to progress, patients' treatment options become extremely limited.

 

For years, Novartis's Lutathera (lutetium-177-labeled somatostatin analog) has been the standard therapy for these patients, and its clinical value has been fully validated. Lutathera's 2024 sales were approximately $816 million, climbing further to around the $816 million level in 2025. This drug has brought survival benefits to tens of thousands of patients.

 

However, Lutathera is not a panacea. Most patients treated with Lutathera eventually experience disease progression, and once progression occurs, follow-on treatment options are virtually nonexistent. It is precisely this unmet clinical need that provided RYZ101 with its entry point.

 

What makes RYZ101 special is the "warhead" it carries. Lutathera uses lutetium-177, a beta particle emitter; RYZ101 chose actinium-225 — an alpha particle emitter. The difference between the two is not merely a substitution of elements. Alpha particles are more massive and higher in energy, capable of releasing powerful killing power within an extremely short distance, theoretically causing more lethal DNA double-strand breaks in tumor cells while causing less damage to surrounding normal tissue.

 

BMS's press release quoted RayzeBio Chief Medical Officer Amreen Husain as saying: "This is the first alpha isotope-targeted radiopharmaceutical therapy to achieve a Phase III result in any indication."

 

On the other hand, the difficulty of developing alpha nuclide therapies lies precisely here.

 

Actinium-225 has a half-life of less than 10 days, meaning the window from production to delivery to the patient is extremely narrow, and supply chain management is far more complex than for traditional drugs. In 2024, precisely because of severe global supply bottlenecks for actinium-225, the ACTION-1 trial involving RYZ101 was halted for patient enrollment.

 

BMS's predicament is not an isolated case, because supply shortages are not coincidental. Only a handful of suppliers worldwide can produce actinium-225 at scale, and rapidly growing demand has stretched the entire supply chain thin.

Fortunately, the supply problem did not escalate into a clinical disaster.

 

In August 2026, BMS announced that RYZ101 received FDA Orphan Drug Designation, based on the significant unmet needs facing GEP-NETs patients.

 

Two months later, on October 12, the interim analysis of ACTION-1 provided the key answer: RYZ101 achieved statistically significant and clinically meaningful improvement in blinded independent central review-assessed PFS compared to investigator's choice of standard therapy (high-dose or high-frequency long-acting somatostatin analogs, everolimus, or sunitinib).

 

In terms of safety, the data were consistent with RYZ101's previously known safety profile, with no new safety signals.

 

BMS did not disclose specific PFS data; complete results will be presented at a future academic conference. OS follow-up is ongoing, and the latter will largely determine its ultimate clinical positioning.

 

Chapter 2: A Massive Bet

 

RYZ101 is becoming BMS's new moat. But looking back to when BMS and RayzeBio tied the knot, there was no shortage of controversy from the outside.

 

At the end of 2023, BMS announced the acquisition of RayzeBio for $62.50 per share in cash, totaling approximately $4.1 billion. RayzeBio was a clinical-stage radiopharmaceutical company that had been listed on Nasdaq for less than three months at the time.

 

Why would a company with no products on the market be worth $4.1 billion — the largest in radiopharmaceutical M&A history? Moreover, RayzeBio's core asset RYZ101 was still in the early stages of Phase III clinical trials for GEP-NETs, not to mention other early-stage indication explorations, still a considerable distance from commercialization.

 

The answer lies in BMS's strategic predicament.

 

BMS is facing the most severe patent cliff in its history. Patent protection for its two ace products, Eliquis and Opdivo, will expire successively, and the market has fully anticipated BMS's revenue gap around 2030.

 

As BMS CEO Chris Boerner has emphasized on multiple public occasions, BMS is actively building a diversified pipeline to hedge against the impact of patent expiration. Radiopharmaceuticals — especially alpha nuclide therapies — happen to provide an extremely attractive entry point.

 

From a technology route perspective, RayzeBio's differentiated advantage lies in its deep bet on actinium-225.

 

Across the radiopharmaceutical field, lutetium-177 is the mainstream isotope that has already been commercialized, with Novartis's Lutathera and Pluvicto both based on this route. But actinium-225 is considered the key to next-generation radiopharmaceuticals, and its stronger killing power and more precise targeting capability have led the industry to widely view it as the next frontier.

 

Therefore, through the acquisition of RayzeBio, BMS directly obtained a platform in a leading position in the alpha nuclide field, not just a single drug.

 

This deal also brought BMS another easily overlooked but crucial asset: RayzeBio's manufacturing facility in Indianapolis. The special nature of radiopharmaceuticals is that they cannot be mass-produced in advance and stored long-term like traditional drugs. Drug production, distribution, and administration must be completed within an extremely short time window. In other words, manufacturing capability itself is a core barrier in radiopharmaceutical competition.

 

RayzeBio's Indianapolis plant is the first facility in the U.S. to integrate isotope production and drug manufacturing at the same site, and it began operations in July 2025.

 

After the acquisition closed, BMS did not stop there.

 

In 2024, BMS completed two important deals through RayzeBio: first, a licensing agreement with Philochem to acquire the prostate cancer new-target radiopharmaceutical OncoACP3 for $1.35 billion; second, expanding its external collaboration network in the radiopharmaceutical field. This series of moves indicates that BMS's radiopharmaceutical layout is not a trial dip, but a systematic strategic investment.

 

The interim analysis results of ACTION-1 disclosed this time at least validate BMS's judgment in direction. Following the announcement, BMS's stock rose nearly 4% in premarket trading. The capital market's reaction says it all.

 

Chapter 3: Full-Scale Exit

 

RYZ101's Phase III success is only one chapter in BMS's radiopharmaceutical story. If we look further, a more complete layout picture can be seen.

 

First, production infrastructure comes first.

 

In August, BMS announced through RayzeBio an investment of $173 million to build a second radiopharmaceutical production facility in Whitestown, Indiana. This new 225,000-square-foot plant will break ground in 2026 and complement the existing Indianapolis facility.

 

BMS expects that by the end of 2029, the two plants will create 100 new jobs with annual salaries exceeding $130,000. The choice of Indiana is no coincidence: the state is within a 10-hour drive of 50% of the U.S. population. For radiopharmaceuticals with extremely short half-lives, the logistics radius is the commercial radius.

 

Second, pipeline depth.

 

Beyond RYZ101, RayzeBio's pipeline also covers multiple solid tumor areas including small cell lung cancer, liver cancer, and prostate cancer.

 

BMS also acquired prostate cancer-targeting radiopharmaceutical OncoACP3 through the Philochem acquisition in 2025. The common feature of these assets is that they are all built on actinium-225 platform technology, sharing the same production facilities and supply chain system. Once this platform matures, the marginal cost of developing new assets will be significantly reduced.

 

Third, the offense and defense of the actinium-225 supply chain.

 

BMS is not the only company that has recognized the strategic value of actinium-225. AstraZeneca acquired FPI-2265 (a PSMA-targeting actinium-225 drug) through the acquisition of Fusion Pharmaceuticals and is building an actinium-225 production base in China. Novartis's Ac-PSMA-617 is also planned to enter Phase III, while Eli Lilly has laid out a lead-212 route through collaboration with AdvanCell.

 

In this race around alpha nuclides, supply chain stability will determine who can achieve commercialization first.

 

BMS's choice is to build capacity in-house while pursuing external partnerships. RayzeBio's Indiana plant already possesses full-chain capability from isotope production to finished drug manufacturing.

 

At the same time, global isotope suppliers are also actively expanding: TerraPower Isotopes has committed $450 million to build a cGMP production facility in Philadelphia, aiming to expand actinium-225 capacity 20-fold; NorthStar Medical Radioisotopes has signed a multi-year collaboration agreement with QSA Global to establish a closed-loop radium-226 supply chain.

 

These upstream investments will gradually ease actinium-225 supply bottlenecks in the coming years, but in the short term, the supply-demand imbalance will persist.

 

Finally, the logic of indication expansion.

 

RYZ101's success in later-line GEP-NETs treatment lays the foundation for its expansion into earlier-line treatment and other SSTR-positive tumors. The TRACY-1 trial's exploration in breast cancer represents a "target-driven, cross-cancer expansion" development strategy. The core assumption of this strategy is that as long as the tumor expresses SSTR receptors, RYZ101 may be able to work.

 

If so, RYZ101's potential indication range will far exceed the rare disease field of GEP-NETs.

 

Chapter 4: The Storm Rises

 

BMS's Phase III success is occurring amid a broader industrial transformation.

 

Currently, Novartis remains the undisputed leader in the radiopharmaceutical field. Pluvicto's full-year 2025 sales reached $1.994 billion, maintaining high-speed growth for two consecutive years. In the first half of 2026, Pluvicto's sales reached $1.3 billion.

 

Novartis is also advancing regulatory applications for Pluvicto in front-line mHSPC treatment, and once approved, the market space will expand significantly.

 

But this giant is not sitting comfortably. Lutathera's dominance in GEP-NETs is facing challenges: BMS's RYZ101 has already proven effective in patients who progressed after Lutathera treatment, effectively establishing a new treatment standard in the later-line market that Novartis has not yet covered.

 

On the other hand, Telix Pharmaceuticals acquired ITM Isotope Technologies for $1.7 billion in September 2026. ITM is a key supplier of lutetium-177 isotope used in Lutathera and Pluvicto. It is not hard to see that Novartis's competitors are penetrating upstream into its supply chain.

 

The catch-up is accelerating. Beyond BMS, AstraZeneca and Eli Lilly have also invested heavily in radiopharmaceuticals.

 

AstraZeneca acquired Fusion Pharmaceuticals for $2.4 billion, with its core asset FPI-2265 being a PSMA-targeting actinium-225 drug directly targeting Pluvicto's later-line market.

 

Eli Lilly acquired Point Biopharma for $1.4 billion to obtain candidates including PNT2002, and has successively achieved multi-faceted布局 from RLT to alpha nuclides through multiple collaborations including Aktis, Radionetics, and AdvanCell. Eli Lilly's radiopharmaceutical pipeline already covers multiple cancer types and technology routes, rapidly growing into a formidable competitor.

 

The M&A paradigm in this track is also upgrading. Currently, deal players value systems more.

 

The $8 billion merger between Curium and Lantheus is the most typical case. Curium possesses a global isotope production system and investigational therapeutic drugs, while Lantheus holds leading diagnostic imaging agents in the U.S. market and a commercialization network. Their merger essentially connects the upstream and downstream of the radiopharmaceutical value chain.

 

This trend of full-value-chain competition is both pressure and opportunity for BMS.

 

The pressure is that competitors are building more complete commercial closed loops through integration; the opportunity is that BMS, through RayzeBio, already possesses a relatively complete platform — from actinium-225 production to drug manufacturing, to clinical development and future commercialization networks. The completeness of this chain is rare among MNCs.

 

Another variable in the global radiopharmaceutical landscape comes from China. China Isotope & Radiation Corporation and Dongcheng Pharmaceutical remain the traditional duopoly in the domestic radiopharmaceutical market, but a batch of innovative companies including Sinotau Pharmaceuticals, Hengrui Medicine, Grand Pharma, and Full-Life Technologies are rapidly making moves, changing the competitive landscape.

 

Multiple institutions predict that the global radiopharmaceutical market will maintain a compound annual growth rate above 12% through 2030, with market size expected to exceed $14 billion. Including RYZ101, as more Phase III data read out and more products gain approval, competition in the radiopharmaceutical track will further intensify.

 

It can be said that RYZ101's Phase III success is not only a report card for BMS's $4.1 billion acquisition of RayzeBio, but also a microcosm of the entire radiopharmaceutical industry's transition from the "lutetium era" to the "actinium era."

BMS has taken this step. Next, it needs to turn this step into a path.

 

References:

1. BMS' $4.1B RayzeBio bet delivers Phase 3 radiopharma win

2. From the Largest M&A Deal to Blockbuster: Cool Reflections Amid the Radiopharmaceutical Boom; Tongxieyi

3. BMS: The Lost Decade?; Tongxieyi

4. Licensed and Acquired: Big Pharma Rushes to the "Nuclear" Battlefield; Tongxieyi

5. Restarting the M&A Season: Biopharma's Next Hotbed; Tongxieyi

6. The Five Overlords of Radiopharmaceuticals: A Battle in a $10 Billion Market; Tongxieyi

7. BMS, A Tempering; Tongxieyi